Analytical Data
-
Gene name
DOCK6
- Application
-
Alternative Names
DOCK6；KIAA1395；Dedicator of cytokinesis Protein 6
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q96HP0
-
Expression Region
全长
-
AA Sequence
full
-
Molecular Weight
229.5 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
DOCK6 is a member of the dedicator of cytokinesis (DOCK) family of guanine nucleotide exchange factors (GEFs), which play a crucial role in regulating cytoskeletal dynamics and cellular movement by activating small GTPases, particularly Rac1. The research surrounding DOCK6 has gained prominence due to its significant implications in various biological processes, including neuronal development, immune response, and cell migration. Deficiencies or mutations in DOCK6 have been associated with severe disorders, such as myopathic congenital muscular dystrophy and the immune deficiency known as Wiskott-Aldrich syndrome. Investigating the structure and function of DOCK6, particularly its role in regulating Rac1 activation and downstream signaling pathways, has become a focal point in understanding its contribution to both normal physiological processes and pathological conditions. The reconstitution of DOCK6 in vitro is essential for dissecting its mechanistic roles and for the potential development of therapeutic strategies targeting diseases linked to its dysfunction. By producing and characterizing recombinant DOCK6, researchers aim to unveil its structural features and functional mechanisms, providing insights into how disturbances in its activity can lead to various health issues. The study of DOCK6 not only enhances our understanding of GEF interactions with GTPases but also presents opportunities for the development of novel interventions in diseases characterized by altered cell motility and immune responses. Thus, the comprehensive analysis of DOCK6 as a recombinant protein holds promise for both basic research and clinical advancements in treating related diseases.
